641 related articles for article (PubMed ID: 15604213)
1. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Ahrén B; Hughes TE
Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.
Deacon CF; Hughes TE; Holst JJ
Diabetes; 1998 May; 47(5):764-9. PubMed ID: 9588448
[TBL] [Abstract][Full Text] [Related]
4. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
Deacon CF; Plamboeck A; Møller S; Holst JJ
Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
[TBL] [Abstract][Full Text] [Related]
5. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.
Ahrén B; Holst JJ; Mårtensson H; Balkan B
Eur J Pharmacol; 2000 Sep; 404(1-2):239-45. PubMed ID: 10980284
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ; Mentlein R
Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
[TBL] [Abstract][Full Text] [Related]
7. PACAP contributes to insulin secretion after gastric glucose gavage in mice.
Filipsson K; Holst JJ; Ahrén B
Am J Physiol Regul Integr Comp Physiol; 2000 Aug; 279(2):R424-32. PubMed ID: 10938228
[TBL] [Abstract][Full Text] [Related]
8. The enteroinsular axis in dipeptidyl peptidase IV-negative rats.
Pederson RA; Kieffer TJ; Pauly R; Kofod H; Kwong J; McIntosh CH
Metabolism; 1996 Nov; 45(11):1335-41. PubMed ID: 8931636
[TBL] [Abstract][Full Text] [Related]
9. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.
Hansotia T; Baggio LL; Delmeire D; Hinke SA; Yamada Y; Tsukiyama K; Seino Y; Holst JJ; Schuit F; Drucker DJ
Diabetes; 2004 May; 53(5):1326-35. PubMed ID: 15111503
[TBL] [Abstract][Full Text] [Related]
10. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
11. Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.
Green BD; Irwin N; Flatt PR
Peptides; 2006 Jun; 27(6):1349-58. PubMed ID: 16406202
[TBL] [Abstract][Full Text] [Related]
12. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
13. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
Fehmann HC; Göke R; Göke B; Bächle R; Wagner B; Arnold R
Biochim Biophys Acta; 1991 Feb; 1091(3):356-63. PubMed ID: 1705823
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
16. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G; Thomaseth K; Ahrén B
Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
[TBL] [Abstract][Full Text] [Related]
17. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
18. What do we know about the secretion and degradation of incretin hormones?
Deacon CF
Regul Pept; 2005 Jun; 128(2):117-24. PubMed ID: 15780431
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
20. Homologous desensitization of the insulinotropic glucagon-like peptide-I (7-37) receptor on insulinoma (HIT-T15) cells.
Fehmann HC; Habener JF
Endocrinology; 1991 Jun; 128(6):2880-8. PubMed ID: 1645253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
